It contains the active ingredient tirzepatide, and it's unique because it's a dual agonist medication, targeting both GLP-1 and GIP receptors in the body
Eden emphasizes clinical oversight, lifestyle integration, and ongoing engagement
The same medication prescribed for obesity instead of diabetes is often excluded even when the diabetes indication is covered
Semaglutide may cause nausea or appetite suppression, while inositol rarely produces side effects beyond mild gastrointestinal adjustment in sensitive individuals
The Food and Drug Administration (FDA) has approved semaglutide for weight management and type 2 diabetes treatment in adults
Dodson JA, Wang Y, Murugiah K, Dharmarajan K, Cooper Z, Hashim S, Nuti SV, Spatz E, Desai N, Krumholz HM